Evidence of histidine and aspartic acid phosphorylation in human prostate cancer cells

Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):161-73. doi: 10.1007/s00210-014-1063-4. Epub 2014 Nov 6.

Abstract

We have developed a method to identify previously undetected histidine and aspartic acid phosphorylations in a human prostate cancer progression model. A phosphoproteome of our cell line model is presented, with correlation of modified protein expression between the three states of cancer: non-tumorigenic, tumorigenic, and metastatic cells. With the described interaction proteins potentially phosphorylated by NM23-H1, cellular responses to motility and conformational change stimuli would be achievable. We detect 20 novel histidine-phosphorylated (pHis) and 80 novel aspartic acid-phosphorylated (pAsp) proteins with diverse functions, such as metabolism, protein folding, and motility. Our data indicate that pHis and pAsp are much more prevalent than previously appreciated and may provide insight into the role of NM23-H1 and signaling events that are critical for metastasis. Using the described method for detecting histidine and aspartic acid phosphorylations and our prostate cancer progression cell system, the potential function of NM23-H1 in suppressing metastasis with a two-component regulation system is discussed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspartic Acid / metabolism*
  • Cell Line
  • Cell Line, Tumor
  • Histidine / metabolism*
  • Humans
  • Male
  • NM23 Nucleoside Diphosphate Kinases / metabolism*
  • Phosphorylation
  • Prostatic Neoplasms / metabolism*
  • Proteomics

Substances

  • NM23 Nucleoside Diphosphate Kinases
  • Aspartic Acid
  • Histidine
  • NME1 protein, human